Identifikatoren & physikalische Daten
| CAS No. | 481-29-8 |
|---|
| Summenformel | C19H30O2 |
|---|
| Durchschnittliche Molmasse | 290,4 g/mol |
|---|
| Monoisotopische Masse | 290,2245802 g/mol |
|---|
| SMILES | C[C@]12CC[C@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12 |
|---|
| InChIKey | QGXBDMJGAMFCBF-LUJOEAJASA-N |
|---|
| PubChem CID | 441302 |
|---|
| ChEMBL | CHEMBL272195 |
|---|
| ChEBI | CHEBI:541975 |
|---|
| EC No. | 207-563-3 |
|---|
| DTXSID | DTXSID20289698 |
|---|
Chemische & physikalische Eigenschaften
| XLogP | 3,7 |
|---|
| Polarare Oberfläche (TPSA) | 37,3 |
|---|
| H-Brücken-Donoren | 1 |
|---|
| H-Brücken-Akzeptoren | 2 |
|---|
| Frei drehbare Bindungen | 0 |
|---|
| Schwere Atome | 21 |
|---|
| Formalladung | 0 |
|---|
| Komplexität | 458 |
|---|
| Lipide | Lipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C19 steroids (androgens) and derivatives [ST0202] |
|---|
| SpringerMaterials Properties | Chemical shift |
|---|
| Human Drugs | Pharmaceuticals |
|---|
| Endocrine Disruptors | Potential endocrine disrupting compound |
|---|
| Collision Cross Section | 162.76 Ų [M+H-H2O]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
|---|
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH302 (39.1%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P318, P321, P330, P362+P364, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 46 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|
| Regulatorische Informationen | Status: Active Update: 23-07-2021 https://echa.europa.eu/registration-dossier/-/registered-dossier/11686Androstan-17-one, 3-hydroxy-, (3.beta.,5.alpha.)-: Does not have an individual approval but may be used under an appropriate group standard |
|---|
| Hazard Classes and Categories | Acute Tox. 4 (39.1%) |
|---|